Original ArticleTranslational OncologyMulticenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
Translational Oncology
Under an Elsevier user license
open archive
Keywords
Non–small cell lung cancer
PD-1
PD-L1
Immunohistochemistry
Immunotherapy
Cited by (0)
Dislcosure: The authors declare no conflict of interest.
© 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc.